AcuCort AB is a Sweden-based pharmaceutical company. The company develops oral films ISICORT, which involve chemical substance glucocorticoid dexamethasone that is used for the treatment of acute allergic reactions, as well as for nausea and vomiting during chemotherapy treatments. AcuCort AB operates mostly in Nordic countries.

Employees

Sector

Drug Retailers

More about the company

Quotes

Date	Price	Change	Volume
22/06/26	SEK 0.5540	+22.84%	1,661,462
18/06/26	SEK 0.4510	-32.69%	3,438,034
17/06/26	SEK 0.6700	+1.52%	99,648
16/06/26	SEK 0.6600	+2.17%	392,043

End-of-day quote SPOTLIGHT STOCK MARKET AB

More quotes

Income Statement and Estimates

More financial data

End-of-day quote SPOTLIGHT STOCK MARKET AB Other stock markets 22/06/2026			5-day change	1st Jan Change
0.5540 ^SEK	+22.84%		-14.24%	-7.67%

06-11	Acucort sees increased partner interest ahead of BIO Convention in the U.S.	FW
05-27	AcuCort CEO: Focus on strengthening presence in existing markets, developing new partnerships, and advancing in the US	FW

Market Cap	135M 13.89M 12.21M 11.25M 10.53M 19.73M 1.32B 20.06M 52.27M 646M 52.16M 51.03M 2.24B	P/E 2024	-3.61x	P/E 2025	-5x
Enterprise Value	108M 11.11M 9.76M 9M 8.42M 15.78M 1.05B 16.05M 41.82M 517M 41.72M 40.82M 1.8B	EV / Sales 2024	11.3x	EV / Sales 2025	17x
Free-Float	36.58%	Yield 2024 *	-	Yield 2025	-

06-11	Acucort sees increased partner interest ahead of BIO Convention in the U.S.	FW
05-27	AcuCort CEO: Focus on strengthening presence in existing markets, developing new partnerships, and advancing in the US	FW
04-28	Acucort reports slight increase in operating loss	FW
04-28	AcuCort AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-13	AcuCort and the FDA Agree on iPSP - Important Step Towards US Market Approval	CI
04-13	AcuCort Makes Progress in US Regulatory Process for Zeqmelit	MT
04-13	Acucort plans to apply for U.S. market approval for Zeqmelit in 2026	RE
04-13	Acucort reaches milestone for US approval of Zeqmelit	FW
02-20	Acucort Reports Expected Minor Earnings Changes – CEO: Glenmark Deal Marks Start of New Phase	FW
02-20	AcuCort AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-22	AcuCort, Glenmark Sign Commercial Agreement for Six European Countries	MT
01-22	AcuCort AB Signs Commercial Agreement with Glenmark Pharmaceuticals for Germany and Five Additional European Countries	CI
01-22	Acucort Signs Binding Agreement with Glenmark for Germany and Five Other European Countries	FW

06-17	AcuCort: AcuCort publishes newsletter with CEO update	PU
06-17	AcuCort publishes newsletter with CEO update	AQ
06-11	AcuCort: AcuCort to attend BIO International Convention in San Diego – focus on strategic partnering discussions	PU
06-11	AcuCort : to attend BIO International Convention in San Diego – focus on strategic partnering discussions	PU
06-11	AcuCort to attend BIO International Convention in San Diego - focus on strategic partnering discussions	AQ

AcuCort AB Share Price

Stocks

ACUC

SE0009695927

Drug Retailers

Valuation: AcuCort AB

Chart: AcuCort AB

Latest news : AcuCort AB

Press Releases: AcuCort AB

Quotes and Performance

Course Extremes

Managers and Directors: AcuCort AB

Other Drug Retailers

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+22.84%
1 week	-14.24%
Current month	-19.71%
1 month	-21.97%
3 months	-4.32%
6 months	-2.64%
Current year	-7.67%

1 week	0.4	0.67
1 month	0.4	0.74
Current year	0.4	0.95
1 year	0.4	0.95
3 years	0.33	1.45
5 years	0.33	4.98
10 years	0.33	9.5

Manager	Title	Age	Since
Jonas Jonas Jönmark CEO	Chief Executive Officer	55	08/08/2020
Anna Cherouvrier Hansson PRN	Corporate Officer/Principal	53	13/10/2025

Director	Title	Age	Since
Anna Maria Albertina Eriksrud BRD	Director/Board Member	68	07/02/2017
Ebba Cecilia Fåhraeus CHM	Chairman	63	31/12/2017
Göran Tornling BRD	Director/Board Member	79	31/12/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACUCORT AB	+22.84%	-14.24%	-25.14%	-61.53%	13.52M
JD HEALTH INTERNATIONAL INC.	-2.01%	-12.03%	-16.16%	-32.86%	13.8B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	0.00%	-7.08%	-24.25%	-29.46%	6.76B
MATSUKIYOCOCOKARA & CO.	-0.84%	-1.16%	-21.00%	-15.12%	5.68B
YIFENG PHARMACY CHAIN CO., LTD.	-0.96%	-6.46%	-16.87%	-37.76%	3.54B
CLICKS GROUP LIMITED	-1.75%	+2.00%	-34.07%	-9.21%	3.41B
NAHDI MEDICAL COMPANY	-0.47%	-0.16%	-22.94%	-43.97%	3.31B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	+0.76%	-4.14%	+0.25%	-42.85%	2.67B
GUARDIAN PHARMACY SERVICES, INC.	-5.96%	-6.88%	+94.39%	-	2.65B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+0.15%	-4.36%	-16.82%	-2.59%	2.48B
Average	+1.21%	-4.19%	-8.26%	-30.59%	4.43B
Weighted average by Cap.	-1.26%	-4.93%	-12.39%	-28.10%

	2024	2025
Net sales	7.72M 794K 697K 643K 602K 1.13M 75.21M 1.15M 2.99M 36.9M 2.98M 2.92M 128M	6.68M 688K 604K 557K 521K 976K 65.13M 993K 2.59M 31.96M 2.58M 2.53M 111M
Net income	-17.4M -1.79M -1.57M -1.45M -1.36M -2.54M -170M -2.58M -6.73M -83.19M -6.72M -6.57M -289M	-26.19M -2.69M -2.37M -2.18M -2.04M -3.83M -255M -3.89M -10.14M -125M -10.12M -9.9M -435M
Net Debt	-2.77M -285K -251K -231K -216K -405K -27.02M -412K -1.07M -13.26M -1.07M -1.05M -46.07M	-27.01M -2.78M -2.44M -2.25M -2.11M -3.95M -263M -4.01M -10.46M -129M -10.43M -10.21M -449M